

# Disseminated BCG Infection after Intravesical Instillation in Bladder Cancer: Early Recognition and Prompt Treatment

Marco Distefano\*

Department of Infectious Diseases Umberto I° Hospital, ASP 8 Siracusa via Testaferrata, 196100 Siracusa, Italy

\*Corresponding author: Marco Distefano, Department of Infectious Diseases, Umberto I° Hospital, ASP 8 Siracusa via Testaferrata, 196100 Siracusa, Italy, Tel: 00-39-0931-724213, Fax: 00-39-0931-724108; E-mail: erdis@tin.it

Received: June 01, 2020; Accepted: June 15, 2020; Published: June 22, 2020

Copyright: © 2020 Distefano M. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

## Abstract

Intravesical administration of Bacillus Calmette-Guérin delay tumor progression, decrease the need for cystectomy, and improve overall survival of non-muscle invasive bladder cancer.

In immunocompetent patients, iBCG is usually well tolerated; but uncommonly, severe local and systemic complications can occur. Definitive diagnosis of BCG infection requires *M. bovis* BCG culture (of bodily fluids or tissue from involved sites) but the fastidious growth nature of BCG in culture and a doubling time of 24 to 48 hours contribute to the difficulty in its isolation.

On suspicion of a systemic disease due to BCG, antituberculous therapy should be initiated. There are no clinical trials and no official guidelines regarding treatment, but as *M. bovis* is usually resistant to pyrazinamide and cycloserine, a regimen that includes isoniazid, rifampicin, ethambutol and a fluoroquinolone, such as levofloxacin, is usually administered for at least 6 months.

clinical response to administration of systemic corticosteroids. By contrast, demonstration of viable organisms in a variety of tissues, including lung, liver, pancreas, and bone marrow supports active infection. The fastidious growth nature in culture and a doubling time of 24 to 48 hours contribute to the difficulty of BCG isolation. Further compounding this controversy are several cases of delayed infection, months to even years after the original BCG administration.

Definitive diagnosis of BCG infection requires *M. bovis* BCG culture (of bodily fluids or tissue from involved sites). A presumptive diagnosis may be made in the setting of positive acid-fast bacilli (AFB) smear, histopathology demonstrating granulomas, and/or positive nucleic acid amplification (NAA) test on fluid or tissue, in the appropriate clinical and epidemiologic setting and no alternative etiology. The sensitivity of AFB smear, mycobacterial culture, and molecular testing is limited. Microbiologic diagnosis was established more frequently among patients with localized BCG infection (53 versus 33 percent). Histopathology demonstrated granulomatous inflammation in 86 percent of cases; the highest yield biopsy sites were lung, bone marrow, and liver. Caseous necrosis is typically absent [5]. NAA tests cannot differentiate between members of the *Mycobacterium tuberculosis* complex. The differential diagnosis of infectious complications associated with iBCG includes: mild post-instillation symptoms, bacterial infection, fungal infection, alternative mycobacterial infection.

Early recognition and prompt treatment of patients with disseminated BCG infection are essential. Suspicion should be high even when smears and cultures are negative.

The treatment of infectious complications associated with iBCG depends on clinical presentation (type and severity) [6]. Mild complications usually require no specific treatment and are self-limiting. On suspicion of a systemic disease due to BCG, antituberculous therapy should be initiated. There are no clinical trials and no official guidelines regarding treatment, but as *M. bovis* is usually resistant to pyrazinamide and cycloserine, a regimen that includes isoniazid, rifampicin, ethambutol and a fluoroquinolone, such as levofloxacin, is usually administered for at least 6 months.

In the setting of extensive miliary involvement and/or respiratory failure, the concomitant administration of glucocorticoids given the

potential role of hypersensitivity in the pathogenesis of the disease, has been associated with clinical improvement in case reports [7,8]. There is no standard regimen for administration of adjunctive glucocorticoids; a reasonable strategy consists of prednisone 40 to 60 mg orally daily for 3 to 5 days, followed by a gradual taper over a few weeks.

## Conclusion

Even if iBCG is a safe procedure rare severe complications can occur. High grade of suspicion should be kept for early recognition of disseminated BCG infection. Prompt treatment of disseminated infection is essential and requires a long course of antibiotics and sometimes steroids.

## References

1. Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, et al. (2017) Bladder cancer incidence and mortality: A global overview and recent trends *EurUrol* 71: 96-108
2. Shelley MD, Mason MD, Kynaston H (2010) Intravesical therapy for superficial bladder cancer: A systematic review of randomised trials and meta-analyses. *Cancer Treat Rev* 36:195-205
3. Lamm DL, van der Meijden PM, Morales A, Brosman SA, Catalona WJ, et al. (1992) Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. *J*